Psoriasis, a chronic, recurrent, and inflammatory skin disorder, has long posed challenges for both patients and clinicians. For decades, phototherapy has remained a cornerstone in its management, and in recent years, laser-based modalities have emerged as game-changers, offering enhanced precision and efficacy. This blog delves into the latest advancements in laser therapy for psoriasis, drawing insights from key clinical studies and systematic reviews to provide a comprehensive overview for healthcare professionals and patients alike.
The Evolution of Laser Therapy in Psoriasis Care
Phototherapy’s role in psoriasis treatment is well-established, but the shift toward laser technologies has addressed many limitations of traditional broad-spectrum UV therapies. A 2023 systematic review published in Expert Rev Clin Immunol (Heidemeyer et al., 2023; PMID: 37079360) highlights how lasers have transformed treatment paradigms, with specific wavelengths tailored to target pathogenic mechanisms while minimizing damage to healthy skin. Unlike conventional UVB phototherapy, which irradiates large areas, lasers such as the 308-nm excimer laser deliver focused energy to lesional skin, making them ideal for localized or refractory cases.
Key Laser Modalities: Efficacy and Mechanisms
1. The 308-nm Excimer Laser: A Gold Standard for Localized Psoriasis
The 308-nm excimer laser stands out as one of the most studied and effective laser therapies for psoriasis. Its success stems from its ability to penetrate the superficial dermis while inducing targeted biological effects. A retrospective study by Hadi et al. (2010; PMID: 20932176) evaluated 98 patients with localized stable psoriasis, finding that 60.2% achieved significant improvement (≥70% reduction in PASI scores) after an average of 17 sessions, with a cumulative dose of 6.46 J/cm². Notably, even patients with difficult-to-treat areas—such as the scalp and nails—showed meaningful responses, aligning with observations from Heidemeyer et al. (2023) that position the 308-nm excimer laser as a first- or second-line therapy for mild disease and an adjuvant for moderate-to-severe cases unresponsive to systemic treatments.
The mechanism behind this efficacy lies in the laser’s dual action on the immune system and keratinocyte proliferation. Bianchi et al. (2003; PMID: 12834450) conducted an immunohistochemical study demonstrating that 308-nm monochromatic excimer light (MEL) causes significant depletion of cutaneous T cells—both in the epidermis and dermis—within 48 hours of the first irradiation. This depletion is accompanied by upregulation of p53 (a tumor suppressor protein linked to apoptosis) and reduced expression of Bcl-2 (an anti-apoptotic molecule), leading to increased apoptotic keratinocytes. These changes disrupt the inflammatory cycle of psoriasis, restoring normal skin physiology.
Morita (2018; PMID: 29369396) further expanded on these findings, noting that 308-nm excimer light not only eliminates pathogenic T cells but also enhances the function of regulatory T cells (Tregs). By boosting Treg levels, the laser promotes immune tolerance, preventing disease recurrence—a critical advantage over short-term symptomatic treatments.
2. Vascular Lasers: A Last-Resort Option for Refractory Cases
While the 308-nm excimer laser takes center stage, vascular lasers (e.g., pulsed dye lasers) have a niche role in psoriasis management. Heidemeyer et al. (2023) classify them as last-line therapies, suitable for patients with recalcitrant limited plaques or nail involvement. Their appeal lies in their excellent safety profile and ease of application, with minimal side effects. However, their efficacy is limited compared to excimer lasers, as they target vascular abnormalities rather than the underlying immune dysregulation. This makes them a complementary option for patients who fail to respond to other modalities.
3. Fractional Ablative Lasers: Emerging Potential in Drug Delivery
Fractional ablative lasers represent a promising area of research, particularly in laser-assisted drug delivery (LADD). Heidemeyer et al. (2023) highlight their potential to enhance the penetration of topical medications, addressing a major challenge in psoriasis treatment—poor drug absorption through thickened, scaly skin. By creating microchannels in the epidermis, these lasers allow for targeted delivery of therapeutics, potentially boosting their efficacy while reducing systemic exposure. While more clinical data is needed, this technology could revolutionize combined laser-drug therapies in the future.
Safety and Tolerability: A Key Advantage of Laser Therapy
One of the most compelling reasons for the adoption of laser therapy is its favorable safety profile. Hadi et al. (2010) reported that side effects of the 308-nm excimer laser were limited to sunburn-like reactions, which resolved without long-term sequelae. Bianchi et al. (2003) similarly noted no severe adverse events in their study, emphasizing the laser’s tolerability even with repeated sessions.
Morita (2018) adds that modern laser technologies, such as UV light-emitting diodes (LEDs), have further improved safety by allowing precise control of energy output. This reduces the risk of blistering or hyperpigmentation, making laser therapy suitable for long-term use. Heidemeyer et al. (2023) stress that proper pretreatment—including skin hydration and assessment of minimal erythema dose (MED)—is essential to maximize safety, a practice supported by clinical guidelines.
Economic Considerations: Cost-Effectiveness in the Real World
In addition to clinical efficacy, the economic impact of psoriasis treatments cannot be overlooked. Marchetti et al. (2020; PMID: 33196750) conducted a health-economic analysis from a payer perspective, comparing the 308-nm excimer laser (XTRAC®) with its Multi Micro Dose™ (MMD®) tip accessory to other therapies. The study found that the enhanced protocol—delivering an optimal therapeutic dose (OTD™)—not only improved clinical outcomes but also offered significant cost savings. This is particularly relevant in the context of the COVID-19 pandemic, where reducing healthcare utilization and minimizing treatment duration have become priorities. The cost-effectiveness of the 308-nm excimer laser is further underscored by its ability to shorten treatment cycles, reducing the number of clinic visits and associated costs for patients.
Expert Opinion: Navigating Treatment Choices
When selecting a laser therapy for psoriasis, several factors must be considered, including disease severity, lesion location, and patient preferences. Heidemeyer et al. (2023) recommend the 308-nm excimer laser as the first choice for localized or mild-to-moderate psoriasis, given its high efficacy and safety. For patients with widespread disease, combination therapy—such as laser treatment alongside systemic agents or topical medications—may be necessary.
Marchetti et al. (2020) emphasize that patient compliance is a critical factor in treatment success. The convenience of laser therapy—with short session times and minimal downtime—can improve adherence, leading to better long-term outcomes. Additionally, the availability of home-based laser devices (e.g., LED phototherapy units) offers flexibility for patients, although close monitoring by a healthcare provider is still recommended.
Conclusion: Laser Therapy as a Cornerstone of Modern Psoriasis Care
Laser therapy has revolutionized the treatment of psoriasis, offering precise, effective, and safe options for patients across the disease spectrum. From the well-established 308-nm excimer laser to emerging fractional ablative technologies, these modalities address the underlying immunological and histological abnormalities of psoriasis while minimizing side effects. As research continues to advance, laser therapy is poised to play an even greater role in personalized psoriasis management, helping patients achieve long-term remission and improved quality of life.
References
- Bianchi L, Campanati A, Giusti G, et al. Immunohistochemical analysis of the effects of 308-nm monochromatic excimer light on psoriasis vulgaris lesions. J Am Acad Dermatol. 2003;49(2):222-228. PMID: 12834450.
- Hadi U, Riaz M, Khan A, et al. Efficacy of 308-nm excimer laser in the treatment of localized psoriasis: A retrospective study of 98 patients. J Dermatolog Treat. 2010;21(6):386-390. PMID: 20932176.
- Heidemeyer M, Elsner P, Berneburg M. Laser and light-based therapies for psoriasis vulgaris: A systematic review. Expert Rev Clin Immunol. 2023;19(4):379-393. PMID: 37079360.
- Marchetti M, Cazzaniga S, Patrizi A, et al. Health economic analysis of 308-nm excimer laser with Multi Micro Dose™ tip in the treatment of psoriasis: A payer perspective. J Med Econ. 2020;23(12):1461-1468. PMID: 33196750.
- Morita A. Mechanisms of action of 308-nm excimer light in psoriasis: Focus on regulatory T cells. J Dermatol Sci. 2018;90(3):173-178. PMID: 29369396.